Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA 30602, USA.
Molecules. 2024 May 19;29(10):2390. doi: 10.3390/molecules29102390.
The FDA has approved several drugs based on the fluorinated nucleoside pharmacophore, and numerous drugs are currently in clinical trials. Fluorine-containing nucleos(t)ides offer significant antiviral and anticancer activity. The insertion of a fluorine atom, either in the base or sugar of nucleos(t)ides, alters its electronic and steric parameters and transforms the lipophilicity, pharmacodynamic, and pharmacokinetic properties of these moieties. The fluorine atom restricts the oxidative metabolism of drugs and provides enzymatic metabolic stability towards the glycosidic bond of the nucleos(t)ide. The incorporation of fluorine also demonstrates additional hydrogen bonding interactions in receptors with enhanced biological profiles. The present article discusses the synthetic methodology and antiviral activities of FDA-approved drugs and ongoing fluoro-containing nucleos(t)ide drug candidates in clinical trials.
美国食品药品监督管理局已经批准了几种基于氟代核苷药效团的药物,目前有许多药物正在临床试验中。含氟核苷(酸)具有显著的抗病毒和抗癌活性。在核苷(酸)的碱基或糖中引入氟原子会改变其电子和空间参数,并改变这些部分的亲脂性、药效学和药代动力学特性。氟原子限制了药物的氧化代谢,并为核苷(酸)的糖苷键提供了酶代谢稳定性。氟的掺入还在受体中展示了额外的氢键相互作用,从而增强了生物特性。本文讨论了已批准的 FDA 药物的合成方法学和抗病毒活性,以及正在临床试验中的含氟核苷(酸)候选药物。